



(51) International Patent Classification:

A61P 9/00 (2006.01) A61K 31/517 (2006.01)

A61P 9/10 (2006.01) A61K 31/519 (2006.01)

A61K 31/4709 (2006.01) A61K 45/06 (2006.01)

A61K 31/505 (2006.01)

(21) International Application Number:

PCT/US2020/013340

(22) International Filing Date:

13 January 2020 (13.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/792,203 14 January 2019 (14.01.2019) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US).

(72) Inventor: **DEB, Arjun**; 10889 Wilshire Blvd., Suite 920, Los Angeles, CA 90095-7191 (US).

(74) Agent: **HALSTEAD, David P.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING CARDIAC INJURY

(57) Abstract: Disclosed herein are methods for treating cardiac injury in a subject, comprising administering an ENPP1 inhibitor. Also disclosed are methods of promoting healing of cardiac tissue in a subject having a cardiac injury, comprising administering an ENPP1 inhibitor. Also disclosed are methods of inhibiting ATP hydrolysis in a cardiac fibroblast the method comprising contacting the cardiac fibroblast with an ENPP1 inhibitor. Also provided herein are ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) inhibitors.



COMPOSITIONS AND METHODS FOR TREATING CARDIAC INJURY**Related Applications**

This application claims the benefit of U.S. Provisional Application No. 62/792,203, filed January 14, 2019, the contents of which are fully incorporated by
5 reference herein.

Statement Regarding Federally Sponsored Research

This invention was made with government support under Grant Number W81XWH-17-1-0464, awarded by the Army Medical Research and Materiel Command and Grant Numbers HL129178, HL137241, awarded by the National
10 Institutes of Health. The government has certain rights in the invention.

Background

Mammalian tissues calcify with age and injury. Analogous to bone formation, osteogenic cells are thought to be recruited to the affected tissue and induce mineralization. In the heart, calcification of cardiac muscle leads to conduction
15 system disturbances and is one of the most common pathologies underlying heart blocks. (Cell Stem Cell (2017) 20(2):218-232.e5). Calcification of soft tissues is a cell--mediated process that resembles bone formation in the skeletal system with calcification of the extracellular matrix by cells capable of mineralization. Pathological mineralization of soft tissues, or ectopic calcification, commonly occurs
20 with tissue injury and degeneration and in common diseases such as diabetes and chronic kidney disease. When it occurs in cardiovascular tissues, ectopic calcification can produce debilitating and sometimes fatal conditions, including coronary insufficiency, heart failure, calcific aortic stenosis, systolic hypertension, and left ventricular hypertrophy. (Circ. Res. (2011) 108(9): 1038-1039). Cell plasticity is also
25 known to play an important physiological role during development and wound healing.

Calcification of the extracellular matrix is critically regulated by the balance of extracellular phosphate (Pi) and pyrophosphate (PPi). Pyrophosphate is generated at the cell surface by the enzyme ectonucleotide pyrophosphatase/phosphodiesterase-1
30 (ENPP1) that breaks down ATP to AMP and PPi. Pyrophosphate promotes

mineralization by serving as a substrate for tissue non-specific alkaline phosphatase that hydrolyzes pyrophosphate to generate inorganic phosphate. Thus, inhibition of ENPPI reduces the amount of PPi formed and subsequent calcification.

As there are currently no drugs available to retard calcification in soft tissues, blood vessels or valves, a significant unmet clinical need exists for identifying agents that can inhibit pathological calcification of tissues.

Summary

In certain aspects, the present disclosure provides methods of treating cardiac injury in a subject, comprising administering an ENPP1 inhibitor.

In certain aspects, the present disclosure provides methods of promoting healing of cardiac tissue in a subject having a cardiac injury, comprising administering an ENPP1 inhibitor. In certain embodiments, the cardiac injury is a myocardial injury. In certain embodiments, the myocardial injury is a myocardial infarction.

In certain aspects, the present invention provides a pharmaceutical preparation suitable for use in a human patient in the treatment of cardiac injury, comprising an effective amount of any of the compounds described herein and one or more pharmaceutically acceptable excipients. In certain embodiments, the pharmaceutical preparations may be for use in treating or preventing a condition or disease as described herein.

In certain aspects, the present invention provides a pharmaceutical preparation suitable for use in a human patient in the promotion of healing of cardiac tissue in a subject having a cardiac injury, comprising an effective amount of any of the compounds described herein and one or more pharmaceutically acceptable excipients.

In certain aspects, the present disclosure provides methods of inhibiting ATP hydrolysis in a cardiac fibroblast, the methods comprising contacting the cardiac fibroblast with an ENPP1 inhibitor.

Brief Description of the Drawings

FIGs. 1A and 1B show calcification in injured hearts in a mouse model of PXE treated with vehicle (A) or ARL67156 (B).


Detailed Description

The present disclosure is based in part on the discovery that ENPP1, a type 2 transmembrane protein, is dramatically expressed by cardiac fibroblasts in the region of injury. ENPP1 hydrolyzes ATP into AMP and PPi, and ATP levels increase by
5 orders of magnitude after myocardial infarction. Increased AMP secondary to increased ENPP1 expression signals to myocytes that subsequently release cytokines or mediators that disrupt wound healing. Inhibition of ENPP1 leads to dramatic and significant acceleration of post-cardiac injury healing. Primary and secondary screening of compounds has now identified small molecule inhibitors of ENPP1, and
10 a monoclonal antibody has now been generated targeting the extracellular catalytic domain of ENPP1. As inhibition of ENPP1 after myocardial infarction leads to significant restoration of cardiac function, ENPP1 inhibitors represent a novel therapeutic strategy for myocardial infarction.


The disclosed methods provide inhibitors of ENPP1, which substantially
15 promote healing of cardiac tissue in a subject having a cardiac injury, such as a myocardial injury.

In certain embodiments, the ENPP1 inhibitor comprises a monoclonal antibody adapted to bind to an extracellular catalytic domain of ENPP1.


Several ENPP1 inhibitors are known in the art. For example, rosmarinic acid
20 (also known as SYL-001) has the following structure:



and is known for its activity as an anti-oxidant and GABA transaminase inhibitor. (See, Sassi, et al. J. Clin. Invest. 2014 124:5385-5397.) Another ENPP1 inhibitor is ARL67156, which has the following structure:



. Its ENPP inhibitory activity has been described by Cote et al. (Eur. J. Pharmacol. 2012 689:139–146) and Levesque et al. (Br. J. Pharmacol. 2007 152:141-150). A third compound with ENPP1 inhibitory activity is a bisphosphonate known as etidronic acid:



5 . Although primarily used for their anti-resorptive effect on bone, first generation bisphosphonates such as etidronic acid can bind to calcium hydroxyapatite in sites of active bone remodeling and, as they are not hydrolyzable, prevent further bone mineralization. It is also an antagonist to vascular mineralization.

10 In certain aspects, the present disclosure provides methods of treating cardiac injury in a subject, comprising administering an ENPP1 inhibitor.

In certain aspects, the present disclosure provides methods of promoting healing of cardiac tissue in a subject having a cardiac injury, comprising administering an ENPP1 inhibitor.








15 In certain embodiments of the disclosure, the cardiac injury is a myocardial injury. Representative myocardial injuries include a myocardial infarction, cardiac hypertrophy, or myocarditis. Preferably, the myocardial injury is a myocardial infarction.


20 In certain embodiments, the ENPP1 inhibitor is administered to the subject within about 3 weeks of the cardiac injury, within about 2 weeks of the cardiac injury or within about 1 week of the cardiac injury. Preferably, the ENPP1 inhibitor is administered to the subject within about 48 hours of the cardiac injury, within about 24 hours of the cardiac injury or within about 12 hours of the cardiac injury. More preferably, the ENPP1 inhibitor is administered to the subject within about 8 hours of

the cardiac injury, within about 4 hours of the cardiac injury or within about 2 hours of the cardiac injury.


In additional embodiments, the methods further comprise reducing cellular AMP levels. In certain embodiments, the ENPP1 inhibitor is a compound

5 selected from rosmarinic acid, etidronic acid,







Chlorpromazine




Disulfiram



Cefotiam





Aurintricarboxylic acid




5 Myricetin

Bisoprolol




Propantheline bromide


Oxytetracycline




Chicago sky blue 6B




L-3,4-dihydroxyphenylalanine




Meclocycline




5 Methacholine chloride




LOPAC-SQ 22536







Lymecycline



LOPAC-L-DOPS




Cefotaxime




5 LOPAC-(-)-Epinephrine

HCl





Topotecan hydrochloride hydrate




LOPAC-MRS 2159

, Pyrocatechol







LOPAC-(-)-alpha-Methylnorepinephrine ,




Topotecan ,




PF-477736 ,




Ceftazidime ,





5 Minocycline ,




ARL67156




Bisdemethoxycurcumin




LOPAC-Ceftriaxone




5 Cefsulodin



LOPAC-R(-)-2,10,11-Trihydroxy-N-propylnoraporphine, and




LOPAC-6-Hydroxy-DL-DOPA, or a pharmaceutically acceptable salt and/or prodrug of any of the foregoing. In certain embodiments, the ENPP1 inhibitor is selected from rosmarinic acid, etidronic acid, mesalamine, pentetic acid, methacycline, benserazide, doxylamine, galloflavin, Nitrofurantoin, Chlorpromazine, Disulfiram, Cefotiam, Aurintricarboxylic acid, Myricetin, Bisoprolol, Propantheline bromide, Oxytetracycline, Chicago sky blue 6B, L-3,4-dihydroxyphenylalanine, Meclocycline, Methacholine chloride, LOPAC-SQ 22536,



Lymecycline, LOPAC-L-DOPS,

Cefotaxime, LOPAC(-)-Epinephrine, Topotecan hydrochloride hydrate, LOPAC-MRS 2159, Pyrocatechol, LOPAC(-)-alpha-Methylnorepinephrine, Topotecan, PF-477736, Ceftazidime, Minocycline, ARL67156, Bisdemethoxycurcumin,



LOPAC-Ceftriaxone, Cefsulodin, LOPAC-R(-)-2,10,11-Trihydroxy-N-propylnoraporphine, and LOPAC-6-Hydroxy-DL-DOPA, or a pharmaceutically acceptable salt thereof.

In certain embodiments, the ENPP1 inhibitor is ceftazidime or a pharmaceutically acceptable salt and/or prodrug thereof, preferably ceftazidime or a pharmaceutically acceptable salt thereof.

In certain embodiments, the ENPP1 inhibitor is ARL67156 or a pharmaceutically acceptable salt and/or prodrug thereof, preferably ARL67156 or a pharmaceutically acceptable salt thereof.

In certain embodiments, the ENPP1 inhibitor is oxytetracycline or a pharmaceutically acceptable salt and/or prodrug thereof, preferably oxytetracycline or a pharmaceutically acceptable salt thereof.


In preferred embodiments, rosmarinic acid and ARL67156, rosmarinic acid and etidronic acid, or ARL67156 and etidronic acid are conjointly administered to the subject.

In certain embodiments, the ENPP1 inhibitor comprises a monoclonal antibody adapted to bind to an extracellular catalytic domain of ENPP1.


In certain embodiments, the method further comprises conjointly administering the ENPP1 inhibitor with a bisphosphonate, e.g. clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, and zoledronate.

In certain aspects, the present disclosure provides methods of inhibiting ATP hydrolysis in a cardiac fibroblast, comprising contacting the cardiac fibroblast with an ENPP1 inhibitor.


In certain embodiments, the ENPP1 inhibitor is selected from rosmarinic acid, etidronic acid, mesalamine, pentetic acid, methacycline, benserazide, doxylamine, galloflavin, Nitrofurantoin, Chlorpromazine, Disulfiram, Cefotiam, Aurintricarboxylic acid, Myricetin, Bisoprolol, Propantheline bromide, Oxytetracycline, Chicago sky blue 6B, L-3,4-dihydroxyphenylalanine, Meclocycline, Methacholine chloride, LOPAC-SQ 22536, Lyme cycline,




, LOPAC-L-DOPS, Cefotaxime, LOPAC-(-)-Epinephrine, Topotecan hydrochloride hydrate, LOPAC-MRS 2159, Pyrocatechol, LOPAC-(-)-alpha-Methylnorepinephrine, Topotecan, PF-477736, Ceftazidime, Minocycline, ARL67156, Bisdemethoxycurcumin,



LOPAC-Ceftriaxone, Cefsulodin, LOPAC-R(-)-2,10,11-Trihydroxy-N-propylnoraporphine, and LOPAC-6-Hydroxy-DL-DOPA, or a pharmaceutically acceptable salt and/or prodrug thereof. In certain preferred embodiments, the ENPP1 inhibitor is selected from rosmarinic acid, etidronic acid, mesalamine, pentetic acid, methacycline, benserazide, doxylamine, galloflavin, Nitrofurantoin, Chlorpromazine, Disulfiram, Cefotiam, Aurintricarboxylic acid, Myricetin, Bisoprolol, Propantheline bromide, Oxytetracycline, Chicago sky blue 6B, L-3,4-dihydroxyphenylalanine, Meclocycline, Methacholine chloride, LOPAC-SQ 22536, Lymecycline,



LOPAC-L-DOPS, Cefotaxime, LOPAC-(-)-Epinephrine, Topotecan hydrochloride hydrate, LOPAC-MRS 2159, Pyrocatechol, LOPAC-(-)-alpha-Methylnorepinephrine, Topotecan, PF-477736, Ceftazidime, Minocycline, ARL67156, Bisdemethoxycurcumin,



LOPAC-Ceftriaxone, Cefsulodin, LOPAC-R(-)-2,10,11-Trihydroxy-N-propylnoraporphine, and LOPAC-6-Hydroxy-DL-DOPA, or a pharmaceutically acceptable salt thereof.

In certain embodiments, the ENPP1 inhibitor is ceftazidime or a pharmaceutically acceptable salt and/or prodrug thereof, preferably ceftazidime or a pharmaceutically acceptable salt thereof.

In certain embodiments, the ENPP1 inhibitor is ARL67156 or a pharmaceutically acceptable salt and/or prodrug thereof, preferably ARL67156 or a pharmaceutically acceptable salt thereof.

5 In certain embodiments, the ENPP1 inhibitor is oxytetracycline or a pharmaceutically acceptable salt and/or prodrug thereof, preferably oxytetracycline or a pharmaceutically acceptable salt thereof.

10 In certain embodiments, two or more disclosed compounds can be conjointly administered to the subject. E.g., rosmarinic acid and ARL67156, or rosmarinic acid and etidronic acid are conjointly administered, or ARL67156 and etidronic acid are conjointly administered. In certain embodiments, rosmarinic acid and etidronic acid, or another bisphosphonate, can be conjointly administered to the subject. In some embodiments, ARL67156 and etidronic acid, or another bisphosphonate can be conjointly administered to the subject.

15 In certain embodiments, the bisphosphonate may be non-nitrogenous, such as clodronate and tiludronate. In alternative embodiments, the bisphosphonate can be nitrogenous, such as pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, and zoledronate.

20 In certain embodiments, the therapeutic may be a prodrug of the ENPP1 inhibitor, e.g., wherein a hydroxyl in the parent compound is presented as an ester or a carbonate, a phosphate or phosphonic acid is presented as an ester or amide derivative, or a carboxylic acid present in the parent compound is presented as an ester. In certain such embodiments, the prodrug is metabolized to the active parent compound in vivo (e.g., the ester is hydrolyzed to the corresponding hydroxyl, or carboxylic acid).

25 In certain embodiments, the cardiac injury is a myocardial injury. In certain embodiments, the myocardial injury is a myocardial infarction, cardiac hypertrophy, or myocarditis. In certain embodiments, the myocardial injury is a myocardial infarction.

30 *Definitions*

The term "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric

subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, quail, and/or turkeys. Preferred subjects are humans.

As used herein, a therapeutic that “prevents” a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.

The term “treating” includes prophylactic and/or therapeutic treatments. The term “prophylactic or therapeutic” treatment is art-recognized and includes administration to the subject of one or more of the disclosed compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the subject) then the treatment is prophylactic (i.e., it protects the subject against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).

The term “prodrug” is intended to encompass compounds which, under physiologic conditions, are converted into therapeutically active agents. A common method for making a prodrug is to include one or more selected moieties which are hydrolyzed under physiologic conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal. For example, esters or carbonates (e.g., esters or carbonates of alcohols or carboxylic acids) and esters or amides of phosphates and phosphonic acids are preferred prodrugs of the present invention.

The term “masking moiety” as used herein, refers to the chemical moiety that is a covalently bound modification of a pharmacophore that renders the compounds of the present invention to which it is attached prodrugs. A masking moiety is cleavable under, for example, acidic conditions, basic conditions, or physiologic conditions.

When the masking moiety is cleaved, the prodrugs are converted to the therapeutically active agents of the present invention. Esters and carbonates can be used to mask hydroxyls, carbamates and amides can be used to mask amines, carboxyls can be masked as esters, etc., and in certain embodiments the precise
5 masking moiety can be selected to be cleaved under conditions particular to a region of the digestive tract. For example, an amine or hydroxyl can be acylated by a 4-aminobutanoyl group, to form a prodrug that can be administered as a salt of the amine. In the acidic conditions of the stomach, the amino group will remain protonated, masking its nucleophilicity. In the more basic conditions of the small
10 intestines, the ammonium group will be deprotonated, revealing the nucleophilic amine, which can nucleophilically attack the amide or ester formed by the butanoyl group, ultimately revealing the amide or ester with the concomitant release of the protecting group as a lactam.

In certain embodiments, compounds of the invention may have one or more
15 chiral centers. In certain such embodiments, compounds of the invention may be enriched in one or more diastereomers or one or more enantiomers. For example, a compound of the invention may have greater than 30% de, 40% de, 50% de, 60% de, 70% de, 80% de, 90% de, or even 95% or greater de. A diastereo-enriched composition or mixture may comprise, for example, at least 60 mol percent of one
20 diastereomer, or more preferably at least 75, 90, 95, or even 99 mol percent. In certain embodiments, the compound enriched in one diastereomer is substantially free of the other diastereomers, wherein substantially free means that the other diastereomers make up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the primary diastereomer, e.g., in
25 the composition or compound mixture. For example, if a composition or compound mixture contains 98 grams of a first diastereomer and 2 grams of a second diastereomer, it would be said to contain 98 mol percent of the first diastereomer and only 2% of the second diastereomer. In certain embodiments, a compound of the invention may have greater than 30% ee, 40% ee, 50% ee, 60% ee, 70% ee, 80% ee,
30 90% ee, or even 95% or greater ee. An enantio-enriched composition or mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 90, 95, or even 99 mol percent. In certain embodiments, the compound

enriched in one enantiomer is substantially free of the other enantiomer, wherein substantially free means that the other enantiomer makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the primary enantiomer, e.g., in the composition or
5 compound mixture. For example, if a composition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2% of the second enantiomer. The compounds of the invention may also be racemic mixtures of enantiomers.

As used herein, single bonds drawn without stereochemistry do not indicate
10 the stereochemistry of the compound.

As used herein, hashed or bolded non-wedge bonds indicate relative, but not absolute, stereochemical configuration (e.g., do not distinguish between enantiomers of a given diastereomer).

As used herein, hashed or bolded wedge bonds indicate absolute
15 stereochemical configuration.

Pharmaceutical Compositions

Compounds of any of the structures described herein and any composition of these compounds may be used in the manufacture of medicaments for the treatment of
20 any diseases or conditions disclosed herein.

The compositions and methods of the present invention may be utilized to treat a subject in need thereof. In certain embodiments, the subject is a mammal such as a human, or a non-human mammal. When administered to subject, such as a human, the composition or the compound is preferably administered as a
25 pharmaceutical composition comprising, for example, a compound of the invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In preferred embodiments, when
30 such pharmaceutical compositions are for human administration, particularly for invasive routes of administration (i.e., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution

is pyrogen-free, or substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as an eye drop.

A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a compound such as a compound of the invention. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for example, a compound of the invention. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

"Pharmaceutically acceptable salt" or "salt" is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.

The term "pharmaceutically acceptable acid addition salt" as used herein means any non-toxic organic or inorganic salt of the disclosed compounds. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen

- 5 orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, bitartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic, salicylic, and sulfosalicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono
- 10 or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of formula I or II are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art.
- 15 Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds of formula I or II for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

The term "pharmaceutically acceptable basic addition salt" as used herein means any non-toxic organic or inorganic base addition salt of any acid compounds

20 disclosed herein. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.

- 25 The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Some examples of materials which can
- 30 serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and

cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); anally, rectally or vaginally (for example, as a pessary, cream or foam); parenterally (including intramuscularly, intravenously, subcutaneously or intrathecally as, for example, a sterile solution or suspension); nasally; intraperitoneally; subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin, or as an eye drop). The compound may also be formulated for inhalation. In certain embodiments, a compound may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U.S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.

The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of

active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.

Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the invention, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the invention suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. Compositions or compounds may also be administered as a bolus, electuary or paste.

To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of

capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular

5 weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked
10 sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and
15 granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes
20 and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active
25 ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

30 Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage

forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations of the pharmaceutical compositions for rectal, vaginal, or urethral administration may be presented as a suppository, which may be prepared by mixing one or more active compounds with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

Formulations of the pharmaceutical compositions for administration to the mouth may be presented as a mouthwash, or an oral spray, or an oral ointment.

Alternatively or additionally, compositions can be formulated for delivery via a catheter, stent, wire, or other intraluminal device. Delivery via such devices may be especially useful for delivery to the bladder, urethra, ureter, rectum, or intestine.

Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically

acceptable carrier, and with any preservatives, buffers, or propellants that may be required.

The ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to an active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the active compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.

Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention. Exemplary ophthalmic formulations are described in U.S. Publication Nos. 2005/0080056, 2005/0059744, 2005/0031697 and 2005/004074 and U.S. Patent No. 6,583,124, the contents of which are incorporated herein by reference. If desired, liquid ophthalmic formulations have properties similar to that of lacrimal fluids, aqueous humor or vitreous humor or are compatible with such fluids. A preferred route of administration is local administration (*e.g.*, topical administration, such as eye drops, or administration via an implant).

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

Pharmaceutical compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable
5 solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols
10 (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

15 These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium
20 chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be
25 accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

30 Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer

employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.

5 For use in the methods of this invention, active compounds can be given *per se* or as a pharmaceutical composition containing, for example, about 0.1 to about 99.5% (more preferably, about 0.5 to about 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

 Methods of introduction may also be provided by rechargeable or
10 biodegradable devices. Various slow release polymeric devices have been developed and tested *in vivo* in recent years for the controlled delivery of drugs, including proteinacious biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a compound at a particular target site.

15 Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

 The selected dosage level will depend upon a variety of factors including the
20 activity of the particular compound or combination of compounds employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and
25 prior medical history of the subject being treated, and like factors well known in the medical arts.

 A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of
30 the pharmaceutical composition or compound at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the

concentration of a compound that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the subject's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the invention. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher *et al.* (1996) Harrison's Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).

In general, a suitable daily dose of an active compound used in the compositions and methods of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

If desired, the effective daily dose of the active compound may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments of the present invention, the active compound may be administered two or three times daily. In preferred embodiments, the active compound will be administered once daily.

In certain embodiments, the ENPP1 inhibitor is administered to the subject within about 2 weeks, 1 week, 48 hours, 24 hours, 12 hours, 8 hours 4 hours, or 2 hours of the cardiac injury.

In certain embodiments, the cellular AMP levels are reduced.

In certain embodiments, compounds of the invention may be used alone or conjointly administered with another type of therapeutic agent. As used herein, the phrase "conjoint administration" refers to any form of administration of two or more different therapeutic compounds such that the second compound is administered while the previously administered therapeutic compound is still effective in the body (*e.g.*, the two compounds are simultaneously effective in the subject, which may include synergistic effects of the two compounds). For example, the different therapeutic compounds can be administered either in the same formulation or in a separate

formulation, either concomitantly or sequentially. In certain embodiments, the different therapeutic compounds can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another. Thus, a subject who receives such treatment can benefit from a combined effect of different therapeutic compounds.

In certain embodiments, a bisphosphonate is conjointly administered with the ENPP1 inhibitor. In certain preferred embodiments, the bisphosphonate is selected from clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, and zoledronate.

In certain embodiments, conjoint administration of compounds of the invention with one or more additional therapeutic agent(s) provides improved efficacy relative to each individual administration of the compound of the invention or the one or more additional therapeutic agent(s). In certain such embodiments, the conjoint administration provides an additive effect, wherein an additive effect refers to the sum of each of the effects of individual administration of the compound of the invention and the one or more additional therapeutic agent(s).

This invention includes the use of pharmaceutically acceptable salts of compounds of the invention in the compositions and methods of the present invention. In certain embodiments, contemplated salts of the invention include, but are not limited to, alkyl, dialkyl, trialkyl or tetra-alkyl ammonium salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, L-arginine, benenthamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, contemplated salts of the invention include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts.

The pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or

crystallization, or adventitious to such solvent.

Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also

5 be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene
10 (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Incorporation by Reference

All publications and patents mentioned herein are hereby incorporated by
15 reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.


Equivalents

While specific embodiments of the subject invention have been discussed, the
20 above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.




We claim:









1. A method of treating cardiac injury in a subject, comprising administering an ENPP1 inhibitor.
2. A method of promoting healing of cardiac tissue in a subject having a cardiac injury, comprising administering an ENPP1 inhibitor.
3. The method of any one of claims 1-2, wherein the cardiac injury is a myocardial injury.
4. The method of claim 3, wherein the myocardial injury is a myocardial infarction, cardiac hypertrophy, or myocarditis.
5. The method of claim 4, wherein the myocardial injury is a myocardial infarction.
6. The method of any one of claims 1-5, wherein the ENPP1 inhibitor is administered to the subject within about 3 weeks of the cardiac injury.
7. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 2 weeks of the cardiac injury.
8. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 1 week of the cardiac injury.
9. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 48 hours of the cardiac injury.
10. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 24 hours of the cardiac injury.
11. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 12 hours of the cardiac injury.

12. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 8 hours of the cardiac injury.
13. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 4 hours of the cardiac injury.
14. The method of claim 6, wherein the ENPP1 inhibitor is administered to the subject within about 2 hours of the cardiac injury.
15. The method of any one of claims 1-14, further comprising reducing cellular AMP levels.
16. The method of any one of claims 1-15, wherein the ENPP1 inhibitor is




selected from rosmarinic acid, etidronic acid, mesalamine ,







Myricetin




, Bisoprolol




Propantheline bromide




Oxytetracycline




Chicago sky blue 6B










L-3,4-dihydroxyphenylalanine




Meclocycline






HCl



H₂O

Topotecan hydrochloride hydrate




LOPAC-MRS 2159


, Pyrocatechol








LOPAC-(-)-alpha-Methylnorepinephrine




Topotecan




PF-477736







LOPAC-Ceftriaxone



Cefsulodin



LOPAC-R(-)-2,10,11-Trihydroxy-N-propylnoraporphine, and



LOPAC-6-Hydroxy-DL-DOPA, or a pharmaceutically acceptable salt and/or prodrug thereof.


17. The method of claim 16, wherein the ENPP1 inhibitor is ceftazidime or a pharmaceutically acceptable salt and/or prodrug thereof.

18. The method of claim 16, wherein the ENPP1 inhibitor is ARL67156 or a pharmaceutically acceptable salt and/or prodrug thereof.



19. The method of claim 16, wherein the ENPP1 inhibitor is oxytetracycline or a pharmaceutically acceptable salt and/or prodrug thereof.

20. The method of claim 16, wherein rosmarinic acid and ARL67156, rosmarinic acid and etidronic acid, or ARL67156 and etidronic acid are conjointly administered to the subject.
21. The method of any one of claims 1-15, wherein the ENPP1 inhibitor comprises a monoclonal antibody adapted to bind to an extracellular catalytic domain of ENPP1.
22. The method of any one of claims 1-21, further comprising conjointly administering a bisphosphonate with the ENPP1 inhibitor.
23. The method of claim 22, wherein the bisphosphonate is selected from clodrate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, and zoledronate.
24. A method of inhibiting ATP hydrolysis in a cardiac fibroblast, the method comprising contacting the cardiac fibroblast with an ENPP1 inhibitor.
25. The method of claim 24, wherein the ENPP1 inhibitor is selected from


rosmarinic acid, etidronic acid, mesalamine




, pentetic acid




methacycline




benserazide ,




doxylamine ,




, galloflavin ,




Nitrofurantoin ,




, Chlorpromazine ,



Disulfiram ,




Cefotiam ,




Aurintricarboxylic acid ,


Myricetin




, Bisoprolol




Propantheline bromide




Oxytetracycline




Chicago sky blue 6B




L-3,4-dihydroxyphenylalanine




Meclocycline





Methacholine chloride




LOPAC-SQ 22536




Lymecycline




LOPAC-L-DOPS




Cefotaxime




LOPAC-(-)-Epinephrine



HCl



H₂O

Topotecan hydrochloride hydrate




LOPAC-MRS 2159


, Pyrocatechol




LOPAC-(-)-alpha-Methylnorepinephrine




Topotecan




PF-477736




Ceftazidime




Minocycline




ARL67156




Bisdemethoxycurcumin







LOPAC-Ceftriaxone



Cefsulodin



LOPAC-R(-)-2,10,11-Trihydroxy-N-propylnoraporphine, and



LOPAC-6-Hydroxy-DL-DOPA, or a pharmaceutically acceptable salt and/or prodrug thereof.

26. The method of claim 24, wherein the ENPP1 inhibitor is ceftazidime or a pharmaceutically acceptable salt and/or prodrug thereof.

27. The method of claim 24, wherein the ENPP1 inhibitor is ARL67156 or a pharmaceutically acceptable salt and/or prodrug thereof.

28. The method of claim 24, wherein the ENPP1 inhibitor is oxytetracycline or a pharmaceutically acceptable salt and/or prodrug thereof.

29. The method of claim 28, wherein the fibroblast is contacted with both rosmarinic acid and ARL67156, rosmarinic acid and etidronic acid, or ARL67156 and etidronic acid.

30. The method of claim 24, wherein the ENPP1 inhibitor comprises a monoclonal antibody adapted to bind to an extracellular catalytic domain of ENPP1.

31. The method of any one of claims 23-30, further comprising contacting the fibroblast with a bisphosphonate.

32. The method of claim 31, wherein the bisphosphonate is selected from clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, and zoledronate.

FIG. 1A





FIG. 1B



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2020/013340

A. CLASSIFICATION OF SUBJECT MATTER IPC (20200101) A61P 9/00, A61P 9/10, A61K 31/4709, A61K 31/505, A61K 31/517, A61K 31/519, A61K 45/06 CPC (20180101) A61P 9/00, A61P 9/10, A61K 31/4709, A61K 31/505, A61K 31/517, A61K 31/519, A61K 45/06 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC (20200101) A61P 9/00, A61P 9/10, A61K 31/4709, A61K 31/505, A61K 31/517, A61K 31/519, A61K 45/06 CPC (20180101) A61P 9/00, A61P 9/10, A61K 31/4709, A61K 31/505, A61K 31/517, A61K 31/519, A61K 45/06 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Databases consulted: Google Scholar, PatBase Search terms used: Query: ENPP1, ectonucleotide, myocardiac, injury, infraction, calcification, inhibitor		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013185214 A1 UNIV LAVAL [CA] 19 Dec 2013 (2013/12/19) [0008],[0027],[0077],[0122],[0140]	1-32
X	Dual effects of bisphosphonates on ectopic skin and vascular soft tissue mineralization versus bone microarchitecture in a mouse model of generalized arterial calcification of infancy. Journal of Investigative Dermatology, 2016, 136.1: 275-283. LI, Qiaoli, et al. 31 Dec 2016 (2016/12/31) abstract, table I	1-32
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "D" document cited by the applicant in the international application "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 05 May 2020		Date of mailing of the international search report 06 May 2020
Name and mailing address of the ISA: Israel Patent Office Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel Email address: pctoffice@justice.gov.il		Authorized officer SEGEV Aharon Telephone No. 972-73-3927165

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2020/013340

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
WO 2013185214 A1	19 Dec 2013	WO 2013185214 A1	19 Dec 2013
